|
Synonyms: NX-210 | NX-210c | NX210c | SCO-spondin derived peptide NX210
Compound class:
Peptide or derivative
Comment: NX210 is a synthetic dodecapeptide that was developed for neuroprotective and neuroregenerative properties [3]. Its amino acid sequence is derived from the thrombospondin type 1 repeat of the neuronal differentiation protein subcommissural organ (SCO)-spondin [2]. Structurally the peptide can establish a cyclic formation through generation of an intrachain disulfide bridge between the two cysteine residues (then referred to as NX210c).
|
| No information available. |
Summary of Clinical Use  |
| Results from a single ascending dose study (EudraCT 2020-000859-12) have been published [1]. A multiple ascending dose clinical trial is ongoing (March 2024). NX210 was designated as an orphan drug for ALS by the FDA, in October 2022. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05827653 | MAD Study of NX210c | Phase 1 Interventional | Axoltis Pharma | ||
